Power vacuum, Alzheimer's trials fuelling Biogen takeover rumours
But analysts remain sceptical Merck & Co and Allergan will actually make an offer for the drugmaker
Add BT as a preferred source
Washington
ON July 21, as Biogen chief executive officer George Scangos announced he would step down, he floated the idea that his company might buy rivals to cement its place near the top of the booming field of biotechnology. Today, Biogen looks more like prey than predator.
Conjecture that the company, a frequent target of rumours in the mergers and acquisitions world, may be acquired increased following a Wall Street Journal report that Merck & Co and Allergan have each considered a takeover. Shares of Biogen spiked in New York on Tuesday, though the Journal said that the talks were informal and preliminary. All three companies declined to comment.
TRENDING NOW
Singtel Q1 gain drops 71% to S$818 million in absence of Airtel stake sale; weaker Singapore business
Sembcorp raises interim dividend despite 72% H1 profit slide to S$150 million on Alinta deal costs
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself
CDL H1 profit jumps three times to S$301 million on strong condo sales, doubles interim dividend
